KLK3 and neoplasm: Blood-based tumor biomarkers have been developed in many cancers for screening and monitoring the tumor, such as alpha-fetoprotein in hepatocellular carcinoma, carcinoembryonic antigen in colorectal cancer, and prostate-specific antigen in prostate cancer (6–8).